Photo of Gordon J. Harris,  PhD

Gordon J. Harris, PhD

Massachusetts General Hospital

Massachusetts General Hospital

Gordon J. Harris, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Professor, Radiology, Harvard Medical School
  • Director, 3D Imaging Service, Massachusetts General Hospital

Research Abstract

I am the co-Director of the DF/HCC Tumor Imaging Metrics Core (TIMC), and Director of the MGH 3D Imaging Service. I am involved in imaging research, focusing on image analysis and visualization techniques, and application of these methods in both research and clinical services. I have developed methods for semi-automated quantitative measurement of tumor volumes, and these methods have been licensed and FDA-approved for clinical use. We created the Precision Imaging Metrics software system manage the workflow, imaging assessments, reporting, auditing, and billing for imaging trials and to provide a centralized quantitative image analysis service for the DF/HCC community. We have licensed this system for use at several other Cancer Centers.

Publications

Powered by Harvard Catalyst
  • Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY, . Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015; 16:e270-e278. PubMed
  • Dilwali S, Patel PB, Roberts DS, Basinsky GM, Harris GJ, Emerick K, Stankovic KM. Primary culture of human Schwann and schwannoma cells: Improved and simplified protocol. Hear Res 2014. PubMed
  • Urban T, Lim R, Merker VL, Muzikansky A, Harris GJ, Kassarjian A, Bredella MA, Plotkin SR. Anatomic and Metabolic Evaluation of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis 1 Using Whole-Body MRI and 18F-FDG PET Fusion. Clin Nucl Med 2014; 39:e301-7. PubMed
  • Merker VL, Bredella MA, Cai W, Kassarjian A, Harris GJ, Muzikansky A, Nguyen R, Mautner VF, Plotkin SR. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A 2014. PubMed
  • Nguyen R, Jett K, Harris GJ, Cai W, Friedman JM, Mautner VF. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J. Neurooncol. 2014; 116:307-13. PubMed
  • Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, Fisher MJ, Goutagny S, Harris GJ, Jaramillo D, Karajannis MA, Korf BR, Mautner V, Plotkin SR, Poussaint TY, Robertson K, Shih CS, Widemann BC, . Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 2013; 81:S33-40. PubMed
  • Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat 2013; 142:405-14. PubMed
  • Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY, . Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol 2013; 14:e396-406. PubMed
  • Smith MJ, Esparza S, Merker VL, Muzikansky A, Bredella MA, Harris GJ, Kassarjian A, Cai W, Walker JA, Mautner VF, Plotkin SR. Plasma S100硫 is not a useful biomarker for tumor burden in neurofibromatosis. Clin Biochem 2013; 46:698-700. PubMed
  • Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol. Neurotol. 2012; 33:1046-52. PubMed
  • Cai W, Yoshida H, Zalis ME, Näppi JJ, Harris GJ. Informatics in Radiology: Electronic Cleansing for Non-cathartic CT Colonography: A Structure-Analysis Scheme. Radiographics 2010; 30:585-602. PubMed
  • Plotkin SR,Halpin C,Blakeley JO,Slattery WH 3rd,Welling DB,Chang SM,Loeffler JS,Harris GJ,Sorensen AG,McKenna MJ,Barker FG 2nd. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 2009; 93:61-77. PubMed
  • Cai W,Kassarjian A,Bredella MA,Harris GJ,Yoshida H,Mautner VF,Wenzel R,Plotkin SR. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology 2009; 250:665-73. PubMed
  • Makris N, Oscar-Berman M, Jaffin SK, Hodge SM, Kennedy DN, Caviness VS, Marinkovic K, Breiter HC, Gasic GP, Harris GJ. Decreased Volume of the Brain Reward System in Alcoholism. Biol Psychiatry 2008; 64:192-202. PubMed
  • Plotkin SR,Singh MA,O'Donnell CC,Harris GJ,McClatchey AI,Halpin C. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol 2008; 5:487-91. PubMed
  • Harris GJ,Plotkin SR,Maccollin M,Bhat S,Urban T,Lev MH,Slattery WH. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 2008; 62:1314-9; discussion 1319-20. PubMed
  • Harris GJ, Jaffin SK, Hodge SM, Kennedy D, Caviness VS, Marinkovic K, Papadimitriou GM, Makris N, Oscar-Berman M. Frontal White Matter and Cingulum Diffusion Tensor Imaging Deficits in Alcoholism. Alcohol Clin Exp Res 2008; 32:1001-13. PubMed
  • Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26:1993-9. PubMed
  • Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008; 29:419-24. PubMed
  • Camargo EC, Furie KL, Singhal AB, Roccatagliata L, Cunnane ME, Halpern EF, Harris GJ, Smith WS, Gonzalez RG, Koroshetz WJ, Lev MH. Acute brain infarct: detection and delineation with CT angiographic source images versus nonenhanced CT scans. Radiology 2007; 244:541-8. PubMed
  • Cai W, Holalkere NS, Harris G, Sahani D, Yoshida H. Dynamic-threshold level set method for volumetry of porcine kidney in CT images in vivo and ex vivo assessment of the accuracy of volume measurement. Acad Radiol 2007; 14:890-6. PubMed
  • Sahani DV, Rastogi N, Greenfield AC, Kalva SP, Ko D, Saini S, Harris G, Mueller PR. Multi-detector row CT in evaluation of 94 living renal donors by readers with varied experience. Radiology 2005; 235:905-10. PubMed
  • Gleason S, Furie KL, Lev MH, O'Donnell J, McMahon PM, Beinfeld MT, Halpern E, Mullins M, Harris G, Koroshetz WJ, Gazelle GS. Potential influence of acute CT on inpatient costs in patients with ischemic stroke. Acad Radiol 2001; 8:955-64. PubMed
  • Lev MH, Segal AZ, Farkas J, Hossain ST, Putman C, Hunter GJ, Budzik R, Harris GJ, Buonanno FS, Ezzeddine MA, Chang Y, Koroshetz WJ, Gonzalez RG, Schwamm LH. Utility of perfusion-weighted CT imaging in acute middle cerebral artery stroke treated with intra-arterial thrombolysis: prediction of final infarct volume and clinical outcome. Stroke 2001; 32:2021-8. PubMed
  • Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J, Sievers A, Yoon YH, Lee EJ, Yang MC, Lewis RF, Harris GJ, Lev M, Schaefer PW, Buchbinder BR, Barest G, Yamada K, Ponzo J, Kwon HY, Gemmete J, Farkas J, Tievsky AL, Ziegler RB, Salhus MR, Weisskoff R. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001; 19:551-7. PubMed
  • McMahon PM, Araki SS, Neumann PJ, Harris GJ, Gazelle GS. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology 2000; 217:58-68. PubMed
Hide